Related Experiment Video

Updated: Aug 29, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.1K

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers

Robert B Scharpf1,2, Archana Balan1, Biagio Ricciuti3

  • 1Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Cancer Research
|September 8, 2022
PubMed

Insights

RAS mutations are common in cancer. This study analyzed over 66,000 tumors, revealing how RAS mutations interact with other genes differently across cancer types, influencing treatment strategies.

Area of Science:

  • Oncology
  • Genomics
  • Cancer Biology

Background:

  • RAS family small GTPases are frequently activated oncogenes in human cancers.
  • Understanding the prevalence and co-alterations of RAS mutations is crucial for cancer research.

Purpose of the Study:

  • To analyze the prevalence of somatic RAS mutations and co-occurring genes in a large cancer cohort.
  • To investigate cancer lineage-specific and context-dependent patterns of RAS mutations and their clinical implications.

Main Methods:

  • Analysis of targeted next-generation sequencing data from the AACR Project GENIE Registry (66,372 tumors).
  • Application of Bayesian hierarchical models to estimate mutation prevalence and co-occurrence.
  • Integrated multiomic analyses of The Cancer Genome Atlas (TCGA) data.

Main Results:

  • Identified differential RAS prevalence and co-mutations across 51 cancer types, varying by cancer lineage, age, sex, and ethnicity.
  • Found specific co-mutational patterns, such as in KRAS G12C-mutant non-small cell lung cancer.
  • Discovered distinct genotype-driven gene expression programs and tumor microenvironment differences in RAS-mutant tumors.
  • Linked genomic findings to differential clinical outcomes and response to immunotherapy.

Conclusions:

  • The genomic landscape of RAS-mutant tumors is complex and cancer lineage-specific.
  • RAS mutations present differential therapeutic vulnerabilities exploitable for combination therapies.
  • Findings support rationally combining RAS-mutant allele-directed therapies with targeted agents and immunotherapy.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.1K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.9K